Archive for March 22nd, 2012
Drugmakers have responded to shrinking sales volume by raising drug prices, and insurers, governments and other payers have borne the costs.
Judges are dismissing lawsuits against generic-drug makers based on a Supreme Court ruling last year that the companies are not liable if they fail to give patients information on potential risks that are not disclosed on the branded version's label. Rep. Henry A. Waxman, D-Calif., said he is exploring ways to hold generic-drug makers liable for not disclosing known risks.
Lawmakers are investigating nearly two dozen phony pharmacies allegedly set up solely to buy and resell crucial drugs in short supply at huge markups. "If it's not illegal, we're going to have to find a way to make it illegal, because this threatens virtually every person in the country," said Rep. Elijah Cummings, D-Md. State officials say pharmacies may be able to get access to scarce drugs when smaller wholesalers can't, on the assumption the drugs will go directly to patients who need them. The lawmakers want detailed information on the businesses by April 11.
Canada's health regulator said it has slapped warnings on prescription drugs marketed by Merck and GlaxoSmithKline that treat enlarged prostates and baldness after finding they could raise the risk of an aggressive form of prostate cancer.
The Supreme Court has tossed out a medical patent [for an autoimmune blood test saying it] used “unpatentable” natural laws … a decision that could affect the burgeoning field of personalized medicine … [as it has lupus UVA1 phototherapy since it was born]